文献速递产科母胎医学

阴道黄体酮联合宫颈环扎术预防早产:系统综述与荟萃分析

Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-05-20

该系统综述与荟萃分析纳入11项研究,评估宫颈环扎术与阴道黄体酮联合治疗对比单一疗法预防早产的效果。联合治疗较单用环扎术或单用黄体酮降低<37周早产风险,并与多项次要结局改善相关;作者认为需进一步开展充分把握度的随机对照试验验证这些有前景的发现。

要点

  • 联合治疗较单用环扎术降低<37周早产风险(RR 0.51,95%CI 0.37-0.79)。
  • 联合治疗较单用黄体酮降低<37周早产风险(RR 0.75,95%CI 0.58-0.96)。
  • 与单用环扎术相比,联合治疗还与<34周、<32周、<28周早产、新生儿死亡减少等相关。

核心结论

  • 宫颈环扎术与阴道黄体酮联合治疗可能比单一疗法更大幅度降低早产,但需进一步开展实施良好且把握度充分的随机对照试验评估这些有前景的发现。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline(Ovid)、EMBASE(Ovid)、PsycINFO(Ovid)、CINAHL(EBSCOhost)、Cochrane Library(Wiley)和Scopus(自建库至2020年)。
  • 纳入随机和半随机对照试验、非随机实验对照试验及队列研究。
  • 纳入对象为被分配接受宫颈环扎术、阴道黄体酮或两者联合以预防早产的高危患者(宫颈长度缩短<25mm或既往早产史),仅评估单胎妊娠。
  • 最终分析纳入11项研究,使用Cochrane协作网偏倚风险评估工具(ROBINS-I和RoB-2)评估偏倚风险,使用GRADE工具评估证据质量。

主要发现

  • 联合治疗较单用环扎术降低<37周早产风险(风险比0.51;95%置信区间0.37-0.79)。
  • 联合治疗较单用黄体酮降低<37周早产风险(风险比0.75;95%置信区间0.58-0.96)。
  • 与单用环扎术相比,联合治疗还与<34周、<32周或<28周早产、新生儿死亡率降低、出生体重增加、孕龄增加及干预至分娩间隔延长相关。
  • 与单用黄体酮相比,联合治疗还与<32周、<28周早产、新生儿死亡率降低、出生体重增加及孕龄增加相关。
  • 其他任何次要结局均无差异。

关键数值与推荐

  • 主要结局为<37周分娩。
  • 次要结局包括<28周、<32周和<34周分娩、分娩时孕龄、干预至分娩间隔天数、未足月胎膜早破、剖宫产、新生儿死亡率、新生儿重症监护病房入住、插管和出生体重。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步开展实施良好且把握度充分的随机对照试验评估这些有前景的发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vaginal progesterone and cervical cerclage are both effective interventions for reducing preterm birth. It is currently unclear whether combined therapy offers superior effectiveness than single therapy. This study aimed to determine the efficacy of combining cervical cerclage and vaginal progesterone in the prevention of preterm birth. DATA SOURCES: We searched Medline (Ovid), EMBASE (Ovid), PsycINFO (Ovid), CINAHL (EBSCOhost), Cochrane Library (Wiley), and Scopus (from their inception to 2020). STUDY ELIGIBILITY CRITERIA: The review accepted randomized and pseudorandomized control trials, nonrandomized experimental control trials, and cohort studies. High risk patients (shortened cervical length <25mm or previous preterm birth) who were assigned cervical cerclage, vaginal progesterone, or both for the prevention of preterm birth were included. Only singleton pregnancies were assessed. METHODS: The primary outcome was birth <37 weeks. Secondary outcomes included birth <28 weeks, <32 weeks and <34 weeks, gestational age at delivery, days between intervention and delivery, preterm premature rupture of membranes, cesarean delivery, neonatal mortality, neonatal intensive care unit admission, intubation, and birthweight. Following title and full-text screening, 11 studies were included in the final analysis. Risk of bias was assessed using the Cochrane Collaboration tool for assessing the risk of bias (ROBINS-I and RoB-2). Quality of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) tool. RESULTS: Combined therapy was associated with lower risk of preterm birth at <37 weeks than cerclage alone (risk ratio, 0.51; 95% confidence interval, 0.37-0.79) or progesterone alone (risk ratio, 0.75; 95% confidence interval, 0.58-0.96). Compared with cerclage only, combined therapy was associated with preterm birth at <34 weeks, <32 weeks, or <28 weeks, decreased neonatal mortality, increased birthweight, increased gestational age, and a longer interval between intervention and delivery. Compared with progesterone alone, combined therapy was associated with preterm birth at <32 weeks, <28 weeks, decreased neonatal mortality, increased birthweight, and increased gestational age. There were no differences in any other secondary outcomes. CONCLUSION: Combined treatment of cervical cerclage and vaginal progesterone could potentially result in a greater reduction in preterm birth than in single therapy. Further, well-conducted and adequately powered randomized controlled trials are needed to assess these promising findings.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Aubin AM, McAuliffe L, Williams K, et al. Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023. PMID: 37211087. doi:10.1016/j.ajogmf.2023.101024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。